New antibiotic candidate BWC0977 enters first human safety trial
NCT ID NCT07029932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety and how the body handles a new antibiotic called BWC0977. It involves 48 healthy adults aged 18 to 55 who will receive either the drug or a placebo by IV. The goal is to find safe doses for future studies targeting drug-resistant bacterial infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-••••
Contact